Skin Cancer Clinical Trial
Official title:
Skin Cancer in Swiss Transplant Cohort Study
It's known that organ transplant recipients with long-term drug-induced immunosuppression have a increase of the life-time incidence of squamous cell carcinoma. This study will analyze the incidence and type of skin cancer in the Swiss Transplant Cohort Study and the association with exposure to immunosuppressive and antiinfective drugs and other parameters like age or gender of organ transplant recipients.
Organ transplant recipients with long-term drug-induced immunosuppression have an increase of
the life-time incidence of squamous cell carcinoma and are also affected at an earlier age
than the general population. In organ transplant recipients prognosis of squamous cell
carcinoma differs due to more rapid growth, less differentiation and higher risk for
metastases in comparison to the general population. Epidemiological data indicate that the
risk of skin neoplasms in organ transplant recipients is related to the cumulative exposure
to immunosuppressive drugs over time. It remains unclear wether this risk differs between
drug classes.
This study is a prospective observational cohort study of kidney, heart, lung, liver,
pancreas and small bowel transplant recipients enrolled into the Swiss Transplant Cohort
Study (STCS).
Since 2008 almost all organ transplant recipients in Switzerland are enrolled to the STCS.
The STCS collects
- baseline patient and case data: date of transplantation, age, gender, type of
transplanted organ, past immunosuppression
- follow-up patient and case data: organ rejection with type and date of rejection, type
of immunosuppression in response to organ rejection, graft loss with date of graft loss,
immunosuppressive drug treatment, other drug treatment, death, drop out, occurrence of
cancer and infections)
- drug exposure data (with start and stop dates): induction immunosuppressive drugs
(Basiliximab, Rituximab, Thymoglobulin, ATG, ATGAM, IG iv, Plasmapheresis), maintenance
immunosuppressive drugs (Cyclosporine A, Glucocorticoids, Tacrolimus, Mycophenolate
mofetil, Everolimus, Azathioprine, Sirolimus, EC-MPA), infectious disease prophylaxis
(e.g. TM-Sulfamethoxazole, Valaciclovir, Fluconazole, Atovaquone, Voriconazole,
Quinolone), other drugs (e.g. Statins, beta-Blockers, oral antidiabetics).
The investigators will statistically illustrate the incidence, prevalence and type of skin
neoplasms in the STCS. The investigators will show the association of the incidence of skin
neoplasms and the exposure to different immunosuppressive drugs, other drugs and other
parameters in the STCS (e.g. age, gender).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05779423 -
Cryoablation+Ipilimumab+Nivolumab in Melanoma
|
Phase 2 | |
Terminated |
NCT01468818 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT01820234 -
Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event
|
N/A | |
Completed |
NCT00535769 -
Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
|
Phase 0 | |
Completed |
NCT00526032 -
Melanoma Detection by Oblique-Incidence Optical Spectroscopy
|
N/A | |
Completed |
NCT00588341 -
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
|
Phase 2 | |
Active, not recruiting |
NCT01447199 -
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
|
||
Enrolling by invitation |
NCT04758988 -
AI Augmented Training for Skin Specialists
|
N/A | |
Not yet recruiting |
NCT04534868 -
Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area
|
N/A | |
Recruiting |
NCT04138342 -
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
|
Phase 1 | |
Completed |
NCT03673917 -
Cosmetology Students and Skin Cancer
|
N/A | |
Recruiting |
NCT04341064 -
Sun-safe Habits Intervention and Education
|
Phase 3 | |
Completed |
NCT04206995 -
Cancer Sensing: Evaluation of Odour Sampling Techniques
|
||
Recruiting |
NCT05574101 -
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05860881 -
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
|
Phase 3 | |
Completed |
NCT05146622 -
Virtual Sun Safe Workplaces Ph I
|
||
Recruiting |
NCT05068310 -
Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
|
||
Recruiting |
NCT03889899 -
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
|
N/A |